INSM Stock Forecast: Insmed, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$141
−2.17% on the day

The 24 Wall Street analysts covering Insmed, Inc. hold a median 12-month price target of $195 — +38.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 76 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$31.7B
Ticker Nerd rank
76/ 100
Median analyst target
$195
Analysts covering
24
Revenue$425.5M+296.1% y/y
Operating income−$101.3M
Net income−$13.2M
Free cash flow−$95.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+16.6%
1M
+47.7%
YTD
−18.8%
1Y
−29.2%
From 52W high
−33.1%
From 52W low
+53.8%
$92
$211
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Insmed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
76/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Quality
96
Growth
93
Volatility
87
Revisions
70
Momentum
43
Accruals
36
Issuance
33

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INSM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INSM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Jan 26Apr 26Jul 26Oct 26INSMHigh $243Median $195Low $158

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says24 analysts
23
Buy
1
Hold
0
Sell
$158
Low
$195
Median
$243
High

The green dot is the last close — the median target sits +38.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
4 Nov 2026HC Wainwright & Co.AssumesBuy$220
2 Nov 2026GuggenheimMaintainsBuy$205 → $201
21 Oct 2026Morgan StanleyMaintainsOverweight$218 → $213
12 Oct 2026HC Wainwright & Co.ReiteratesBuy$220
12 Oct 2026Wolfe ResearchDowngradePeer Perform—
30 Sept 2026BarclaysMaintainsOverweight$237 → $207
24 Sept 2026Goldman SachsReinstatesBuy$188
15 Sept 2026Roth CapitalReiteratesBuy$212 → $198
10 Aug 2026JP MorganMaintainsOverweight$179 → $175
10 Aug 2026Truist SecuritiesReiteratesBuy$185 → $195
7 Aug 2026Evercore ISI GroupMaintainsOutperform$160 → $170
7 Aug 2026GuggenheimMaintainsBuy$207 → $205
7 Aug 2026Wells FargoMaintainsOverweight$161 → $169
21 July 2026BMO CapitalInitiatesOutperform$192
15 July 2026Wells FargoMaintainsOverweight$160 → $161
10 July 2026GuggenheimReiteratesBuy$207
22 June 2026Evercore ISI GroupMaintainsOutperform—
8 June 2026JP MorganMaintainsOverweight—
5 June 2026RBC CapitalMaintainsOutperform—
14 May 2026Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INSM.

Market Radar

This page is one stock. Monday covers all of them.

INSM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INSM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Insmed, Inc. returned −29.2% against +6.9% for the S&P 500, dividends included.

INSM vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26INSMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INSM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
9
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
21.1×

Cheaper than 7% of US stocks

Price / book
44.1×

Cheaper than 2% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
84.2%

Higher than 93% of US stocks

Operating margin
−41.7%

Higher than 19% of US stocks

Net margin
—
Returns & dividend
Return on equity
−72.5%

Higher than 17% of US stocks

Return on assets
−17.3%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Insmed, Inc. has a market value of $31.7B and an enterprise value of $31.3B.

  • Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter grew 296.1% year on year.

  • Net income over the same four quarters: −$875.3M, a −76.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$4.11.

  • Free cash flow in the twelve months to 30 June 2026: −$807.7M.

  • Shares outstanding: 218.3M.

  • forward P/E: 227.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Insmed, Inc. employs 1,664 people — $684K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

INSM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INSMInsmed, Inc.$31.7B76
RVMDRevolution Medicines, Inc.$33.6B56
ROIVRoivant Sciences Ltd.$27.7B83
RPRXRoyalty Pharma Plc$39.4B97
INCYIncyte Corp.$22.9B89
ALNYAlnylam Pharmaceuticals, Inc.$19.3B58
ASNDAscendis Pharma A/S$16.6B93

Take a look at INSM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Insmed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about INSM

What is the INSM stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Insmed, Inc. have a median 12-month price target of $195, with estimates ranging from $158 to $243. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INSM stock a buy right now?

Of the 24 analysts covering Insmed, Inc., 23 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Insmed, Inc. 76 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INSM?

As at 21 Nov 2026, Insmed, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will INSM stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +38.0% from the last close, and Ticker Nerd's factor model ranks Insmed, Inc. 76 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INSM stock forecast for 2030?

No analyst covering Insmed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $158 to $243 over the next 12 months.

How has INSM stock performed over the past year?

Insmed, Inc. returned -29.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Insmed, Inc. do?

Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions.

Company

About Insmed, Inc.

Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions. The company’s pipeline emphasizes innovative approaches such as oral therapies and inhaled medicines designed to address difficult-to-treat respiratory disorders. Insmed also conducts research across multiple scientific platforms, including protein engineering and other advanced drug-development technologies. Headquartered in Bridgewater, New Jersey, Insmed serves patients and healthcare providers in the United States, Europe, Japan, and other international markets, positioning itself as a specialist in rare-disease and specialty respiratory treatment.

CEO Mr. William H. Lewis J.D., M.B.A. · 1,664 employees · United States · https://www.insmed.com